1. Scrip
  2. >>Business

1Q Earnings Preview: What To Expect From US, EU Big Hitters

 
• By Scrip Team

The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.

Bernstein analysts expect Eli Lilly & Co. and several other big pharma companies that report earnings in US dollars to get a boost from the continued strengthening of the US dollar, creating a foreign exchange headwind after recent quarters when exchange rates hurt pharma revenues. Bernstein's Tim Anderson expects the company to report $0.88 in earnings per share (EPS) and $5bn in first quarter revenue, including a boost from recent sales growth for diabetes starJardiance (empagliflozin), which Lilly recently said it would test as a treatment for heart failure. Consensus estimates are for $4.8bn in revenue and EPS of $0.85. Investors will look for early sales figures from new products, including the recently approved Taltz (ixekizumab) for psoriasis (Also see "FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx " - Scrip, 23 March, 2016.).

As for future growth, expect analysts to derive new insights from Lilly executives about the company's most anticipated clinical data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

More from Scrip

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.